Vivo Capital, LLC Verona Pharma PLC Transaction History

Vivo Capital, LLC

$368 Million
Q1 2025

A detailed history of Vivo Capital, LLC transactions in Verona Pharma PLC stock. As of the latest transaction made, Vivo Capital, LLC holds 1,438,785 shares of VRNA stock, worth $135 Million. This represents 24.79% of its overall portfolio holdings.

Number of Shares

1,438,785

Previous 2,283,975 37.01%

Holding current value

$135 Million

Previous $106 Million 13.88%

% of portfolio

24.79%

Previous 20.7%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	SELL	$44.81 - $69.63 $37.9 Million - $58.9 Million	-845,190 Reduced 37.01%	1,438,785 $91.3 Million
Q4 2024 Feb 13, 2025	SELL	$28.71 - $47.02 $36.3 Million - $59.5 Million	-1,265,783 Reduced 35.66%	2,283,975 $106 Million
Q2 2024 Aug 14, 2024	SELL	$11.48 - $17.02 $693,610 - $1.03 Million	-60,419 Reduced 1.67%	3,549,758 $51.3 Million
Q1 2024 Apr 22, 2024	SELL	$15.3 - $20.24 $9.79 Million - $12.9 Million	-639,741 Reduced 15.05%	3,610,177 $58.1 Million
Q3 2022 Nov 14, 2022	BUY	$4.14 - $13.59 $6.21 Million - $20.4 Million	1,500,000 Added 54.55%	4,249,918 $43.4 Million
Q3 2021 Nov 15, 2021	SELL	$5.29 - $6.35 $1.58 Million - $1.9 Million	-298,589 Reduced 9.79%	2,749,918 $15.1 Million
Q3 2020 Nov 13, 2020	BUY	$4.45 - $10.2 $6.92 Million - $15.9 Million	1,555,556 Added 104.19%	3,048,507 $19 Million
Q1 2020 May 15, 2020	BUY	$2.16 - $7.28 $3.22 Million - $10.9 Million	1,492,951 New	1,492,951 $6.15 Million
Q3 2019 Nov 13, 2019	SELL	$4.03 - $5.44 $6.02 Million - $8.12 Million	-1,492,951 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$11.96 - $16.95 $17.9 Million - $25.3 Million	1,492,951	1,492,951 $22.9 Million

Others Institutions Holding VRNA

# of Institutions

291

Shares Held

74.3M

Call Options Held

933K

Put Options Held

1.98M

View Full List

About Verona Pharma plc

Ticker VRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,954,200
Market Cap $5.71B
Description
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...

More about VRNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vivo Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vivo Capital, LLC with notifications on news.

Account